tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

KZIA Stock Latest News

Kazia Therapeutics Advances Cancer Research Amid Nasdaq Compliance Challenge
Company AnnouncementsKazia Therapeutics Advances Cancer Research Amid Nasdaq Compliance Challenge
2d ago
6K
KZIA
Kazia Therapeutics trading halted, news pending
PremiumThe Fly
Kazia Therapeutics trading halted, news pending
1M ago
KZIA
Kazia Therapeutics Announces ADS Ratio Change to Maintain Nasdaq Compliance
PremiumCompany Announcements
Kazia Therapeutics Announces ADS Ratio Change to Maintain Nasdaq Compliance
1M ago
6K
KZIA
Kazia Therapeutics Sells Cantrixil IP Rights to Vivesto for $1 Million
PremiumCompany Announcements
Kazia Therapeutics Sells Cantrixil IP Rights to Vivesto for $1 Million
2M ago
6K
KZIA
Kazia Therapeutics sells IP, trademarks rights to Cantrixil for $1M
PremiumThe Fly
Kazia Therapeutics sells IP, trademarks rights to Cantrixil for $1M
2M ago
KZIA
Kazia Therapeutics Advances Cancer Drug Development with Strategic Moves and Promising Trial Results
PremiumCompany AnnouncementsKazia Therapeutics Advances Cancer Drug Development with Strategic Moves and Promising Trial Results
2M ago
6K
KZIA
Kazia Therapeutics: Buy Rating Driven by Dual Potential in GBM and Parkinson’s Disease
Premium
Ratings
Kazia Therapeutics: Buy Rating Driven by Dual Potential in GBM and Parkinson’s Disease
3M ago
KZIA
Kazia Therapeutics Awarded Research Grant to Explore Paxalisib’s Potential for Parkinson’s Treatment
Premium
Company Announcements
Kazia Therapeutics Awarded Research Grant to Explore Paxalisib’s Potential for Parkinson’s Treatment
3M ago
6K
KZIA
Kazia Therapeutics announces research grant awarded from MJFF
PremiumThe Fly
Kazia Therapeutics announces research grant awarded from MJFF
3M ago
KZIA
Maxim starts Kazia Therapeutics at Buy amid ‘positive’ GBM study data
PremiumThe Fly
Maxim starts Kazia Therapeutics at Buy amid ‘positive’ GBM study data
3M ago
KZIA
Kazia Therapeutics initiated with a Buy at Maxim
PremiumThe Fly
Kazia Therapeutics initiated with a Buy at Maxim
3M ago
KZIA
Kazia Therapeutics Highlights Ongoing Oncology Drug Development Progress
PremiumCompany Announcements
Kazia Therapeutics Highlights Ongoing Oncology Drug Development Progress
3M ago
6K
KZIA
Kazia Therapeutics Launches Innovative Breast Cancer Trial with Paxalisib and Immunotherapy
PremiumCompany AnnouncementsKazia Therapeutics Launches Innovative Breast Cancer Trial with Paxalisib and Immunotherapy
4M ago
6K
KZIA
Kazia Therapeutics launches trial of paxalisib/immunotherapy combination
Premium
The Fly
Kazia Therapeutics launches trial of paxalisib/immunotherapy combination
4M ago
KZIA
Kazia Therapeutics Issues Prefunded Warrant for ADS Purchase
Premium
Company Announcements
Kazia Therapeutics Issues Prefunded Warrant for ADS Purchase
4M ago
6K
KZIA
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
PremiumThe Fly
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
4M ago
KZIA
Kazia Therapeutics Charts Path Forward for Paxalisib After FDA Feedback
PremiumCompany Announcements
Kazia Therapeutics Charts Path Forward for Paxalisib After FDA Feedback
5M ago
6K
KZIA
Kazia announces FDA says OS data supports standard, not accelerated approval
PremiumThe Fly
Kazia announces FDA says OS data supports standard, not accelerated approval
5M ago
KZIA
Kazia Therapeutics Presents Promising Data on Paxalisib for Breast Cancer Treatment
PremiumCompany Announcements
Kazia Therapeutics Presents Promising Data on Paxalisib for Breast Cancer Treatment
5M ago
6K
KZIA
Kazia Therapeutics Secures Nasdaq Compliance
PremiumCompany AnnouncementsKazia Therapeutics Secures Nasdaq Compliance
6M ago
6K
KZIA
Kazia Therapeutics management to meet with Maxim
Premium
The Fly
Kazia Therapeutics management to meet with Maxim
6M ago
KZIA
Kazia Therapeutics Advances Paxalisib with FDA Meeting
Premium
Company Announcements
Kazia Therapeutics Advances Paxalisib with FDA Meeting
6M ago
6K
KZIA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >